FP08-1 Resveratrol Supplementation Ameliorates the Effects of High Fat Diet Consumption On Uterine Blood Flow and Placental Inflammation in a Nonhuman Primate Model

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: FP08-Obesity: Novel Mechanisms of Body Weight Regulation
Saturday, June 15, 2013: 11:00 AM-11:30 AM
Presentation Start Time: 11:00 AM
Room 301 (Moscone Center)

Poster Board SAT-721
Victoria HJ Roberts*1, Jessica L Walker1, Kent L Thornburg2, Kevin L Grove1 and Antonio E Frias Jr.3
1Oregon Health and Science University/ONPRC, Beaverton, OR, 2Oregon Hlth Sci Univ, Portland, OR, 3Oregon Health and Science University, Portland, OR
Resveratrol (Resv), a naturally occurring polyphenol, is widely reported to be a calorie restriction mimetic with vasodilatory and anti-inflammatory effects. We have previously demonstrated in our nonhuman primate (NHP) model that consumption of a high fat diet (HFD, 36% fat calories) results in decreased maternal uterine artery blood flow (Quta) with an associated increase in placental injury and risk of stillbirth. The objectives of this study were to test the hypotheses that resveratrol improves Quta in pregnant animals maintained on a HFD with Resv supplementation (HFD + Resv) and that placental inflammation would be ameliorated following dietary intervention. Pregnant Japanese Macaques were fed either a standard chow diet (control, n=11), HFD (n=15) or HFD + Resv (0.37% Resv in HFD chow, n=7). Doppler ultrasound (US) was performed at ~120 days (term=175 days) to measure Quta. Maternal and fetal plasma and placental tissue were collected at C-section delivery at 130 days. Plasma samples were assayed for Resv levels. Placental protein supernatants were prepared for ELISAs. Resv supplementation resulted in significant maternal weight loss and improved insulin sensitivity despite the continued consumption of a HFD. Quta was significantly diminished in HFD vs. control animals as previously reported (p<0.05), yet Quta in the Resv group were completely normalized. Circulating plasma Resv levels were elevated in both maternal and fetal Resv vs. control animals at delivery (Maternal: 0.499 ± 0.36ng/ml vs. 0.131 ± 0.04ng/ml, Fetal: 0.749 ± 0.57ng/ml vs. 0.134 ± 0.02ng/ml respectively).  By ELISA, we demonstrated a significant elevation in RANTES, Serpine 1 and MIF expression (p<0.05) and an insignificant trend towards increased IL-1β, IL-6 and IL-8 in HFD vs. control. The effects of HFD on placental inflammation were reversed by Resv. The beneficial effects of Resv as a dietary supplement are apparent in the improvements to maternal phenotype and placental inflammation however the longer-term effects on fetal development and neonatal outcome remain to be determined. Resveratrol may be a suitable dietary supplement for individuals who consume a HFD during pregnancy in order to improve uterine blood flow and placental development.

Nothing to Disclose: VHR, JLW, KLT, KLG, AEF Jr.

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

Sources of Research Support: NIH/NIDDK grant R24 DK090964 awarded to KG and KT. P51 OD011092 (KG and AF).
Previous Abstract | Next Abstract >>